Ending the Allure of Drug Advertising
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.
ACHP calls on Congress to curb direct-to-consumer (DTC) drug ad dominance. Patients should be able to access affordable, necessary medications, rather than being swayed by misleading marketing tactics.
ACHP sent a letter to FDA’s Acting Commissioner, Sara Brenner, with comments on the Expedited Program for Serious Conditions.
For patients suffering from rare, debilitating diseases, cell and gene therapies offer a source of hope. These innovative treatments are tailored to individual patients’ DNA, which makes them uniquely effective. But there is one major problem – the staggeringly high price tag.
ACHP recently sent a letter to Congress expressing the health care priorities we hope to see before the legislative session concludes.
ACHP submitted a comment letter to the United States Patent and Trademark Office on double patenting, or “patent thickets.”